Maxvoid Plus 8 Tablet contains a combination of Silodosin (8 mg) and Dutasteride (0.5 mg), formulated for the management of benign prostatic hyperplasia (BPH). Silodosin is a selective alpha-1 adrenergic receptor antagonist that acts by relaxing the smooth muscles of the prostate and bladder neck, thereby improving urine flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. Dutasteride is a 5-alpha-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. By reducing DHT levels, Dutasteride helps to shrink the prostate gland over time, improving urinary symptoms and decreasing the risk of acute urinary retention and the need for surgical intervention. The combined action of Silodosin and Dutasteride provides both immediate symptom relief and long-term reduction in prostate size. Maxvoid Plus 8 is typically prescribed for adult males diagnosed with moderate to severe BPH. Patients should be monitored for potential side effects such as dizziness, hypotension, ejaculation disorders, and signs of allergic reactions. It is contraindicated in patients with severe liver impairment or hypersensitivity to any component. Consultation with a healthcare professional is essential before initiating therapy.